Yamo Pharmaceuticals Email Format
Biotechnology ResearchNew York, United States2-10 Employees
Yamo Pharmaceuticals is a biotechnology research company based in New York, United States. It is developing L1-79, a novel therapy aimed at addressing core symptoms of autism by acting on both the central nervous system and metabolic aspects. The company operates with a small staff and focuses on advancing this candidate through clinical development. Its target market comprises individuals diagnosed with autism spectrum disorder, for whom L1-79 could offer a treatment option addressing core symptom domains. In clinical testing to date, the therapy has been well tolerated by trial participants. In May 2025, Yamo Pharmaceuticals disclosed positive Phase 2 results for L1-79 at the 2025 INSAR Annual Meeting.